Answers are grounded in this paper and cite their sources.
In patients with active RA who received ozoralizumab in combination with MTX, the signs and symptoms of RA were significantly reduced as compared with the outcomes in those receiving placebo. Ozoralizumab demonstrated acceptable tolerability with no new safety signals when compared with other antibodies against tumor necrosis factor.
No takes yet. Share an insight, caveat, or question.
Takeuchi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: